US 11,964,008 B2
Method for inactivating zika virus and for determining the completeness of inactivation
Jill A. Livengood, Cambridge, MA (US); Holli Giebler, Cambridge, MA (US); Hansi Dean, Cambridge, MA (US); Tatsuki Satou, Hakari (JP); Raman Rao, Singapore (SG); Jackie Marks, Cambridge, MA (US); Mark Lyons, Cambridge, MA (US); Asae Shintani, Hakari (JP); James Gifford, Cambridge, MA (US); and Sushma Kommareddy, Cambridge, MA (US)
Assigned to Takeda Vaccines, Inc., Cambridge, MA (US)
Filed by TAKEDA VACCINES, INC., Cambridge, MA (US)
Filed on Sep. 13, 2022, as Appl. No. 17/931,887.
Application 17/931,887 is a continuation of application No. 16/761,340, granted, now 11,478,541, previously published as PCT/US2018/059227, filed on Nov. 5, 2018.
Claims priority of provisional application 62/581,500, filed on Nov. 3, 2017.
Claims priority of provisional application 62/592,995, filed on Nov. 30, 2017.
Prior Publication US 2023/0145065 A1, May 11, 2023
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24034 (2013.01); C12N 2770/24071 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); C12N 2770/24164 (2013.01)] 30 Claims
 
1. A pharmaceutical composition comprising an inactivated Zika virus preparation, wherein the inactivated Zika virus preparation comprises less than 1.0 TCID50 of residual replicating virus.